Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Drug Interactions. Found 7 abstracts

Balaburski GM, Dardes RC, Johnson M, Haddad B, Zhu F, Ross EA, Sengupta S, Klein-Szanto A, Liu H, Lee ES, Kim H, Jordan VC. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010 Aug;37(2):387-98.   PMCID: PMC3023309
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Davey MP. Cancer treatments. Imatinib mesylate. Clinical Journal of Oncology Nursing. 2002 Mar;6(2):118-20.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001 Jul 15;61(14):5491-8.
Held-Warmkessel J. Methotrexate. Clinical journal of oncology nursing. 2000 Jul;4(4):187-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Drug Interactions

Drug Interactions adverse effects drug therapy Female pharmacology metabolism Paclitaxel administration & dosage pathology chemically induced methods Dacarbazine Cultured Tumor Cells Oncologic Nursing nursing Aged Adult Drug Monitoring Human Alkylating Antineoplastic Agents Xenograft Model Antitumor Assays Middle Aged Male Patient Education Antineoplastic Agents therapeutic use pharmacokinetics pd [Pharmacodynamics] Drug Administration DNA Repair Enzymes bi [Biosynthesis] Metabolic Clearance Rate Interstitial Lung Diseases Tumor Cell Line Proto-Oncogene Proteins c-bcl-2 EC 3-6-1-3 (Adenosinetriphosphatase) Sesquiterpenes Guanine pa [Pathology] DNA-Binding Proteins etiology Patient Education as Topic analogs & derivatives 0 (Neoplasm Proteins) drug effects dt [Drug Therapy] EC 6-5-1 (DNA Repair Enzymes) ad [Administration and Dosage] nu [Nursing] Myeloid Leukemia adverse Feasibility Studies Hormonal Antineoplastic Agents Adenosinetriphosphatase Neoplasms US Gov't Support-PHS Animal Monoclonal Antibodies Nurse's Role Selective Estrogen Receptor Modulators analogs & me [Metabolism] 73-40-5 (Guanine) Dialysis Solutions Estrogens effects Antineoplastic Antimetabolites Cohort Studies Methotrexate Neoplasm Drug Resistance Phytogenic Antineoplastic Agents Premedication Phenotype derivatives Microdialysis Ovarian Neoplasms pd [Pharmacology] Phytogenic) 0 (Antineoplastic Agents de [Drug Effects] 0 (Proto-Oncogene Proteins c-bcl-2) Diarrhea Antineoplastic Combined Chemotherapy Protocols Protein-Tyrosine Kinases Stomatitis 0 (cyclin-dependent kinase Inhibitor p21) Raloxifene Hydrochloride Cell Cycle human) EC 3-6-1 (PMS2 protein EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) Carboplatin Hemorrhage 85622-93-1 (temozolomide) Estrogen Antagonists Glioma O(6)-Methylguanine-DNA Methyltransferase Alkylating) 0 (Antineoplastic Agents Angiogenesis Inhibitors 0 (Cyclins) Multiple Drug Resistance Drug Eruptions Neoplasm Proteins Protein p53 Rats blood Drug Delivery Systems 33069-62-4 (Paclitaxel) Patient Selection 80 and over Aged Hypertension chemistry Doxorubicin 23214-92-8 (Doxorubicin) mammalian) 0 (MLH1 protein 19916-73-5 (O(6)-benzylguanine) aa [Analogs & Derivatives] 4342-03-4 (Dacarbazine) 0 (Protein p53) Peritoneal Neoplasms Polyglutamic Acid Fallopian Tube Neoplasms Carcinoma antagonists & inhibitors ph [Physiology] ae [Adverse Effects] Mice Nude Rats Bone Marrow Diseases Cyclins Experimental Neoplasms Cell Proliferation Antitumor Drug Screening Assays 0 (DNA-Binding Proteins) Experimental Mammary Neoplasms Paronychia
Last updated on Wednesday, February 05, 2020